Psychiatry Research
Volume 179, Issue 2 , Pages 139-146 , 30 September 2010

Effects of benzodiazepine treatment on cortical GABAA and muscarinic receptors: Studies in schizophrenia and rats

  • Mark C. McLeod

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The Department of Psychiatry, The University of Melbourne, Victoria, Australia
    • ,
  • Elizabeth Scarr

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The Centre for Neuroscience, The University of Melbourne, Victoria, Australia
    • ,
  • Brian Dean

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    • The Department of Psychiatry, The University of Melbourne, Victoria, Australia
    • The Department of Psychological Medicine, Monash University, Clayton, Victoria, Australia
    • Corresponding Author InformationCorresponding author. The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Locked Bag 11, Parkville, Victoria, 3052, Australia. Tel.: +61 3 9389 2940; fax: +61 3 9387 5061.

Received 15 October 2008 ,Revised 24 March 2009 ,Accepted 25 March 2009.

References 

  1. Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin RM, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 1999;20:650–661
  2. Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney WE, et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cerebral Cortex. 1995;5:550–560
  3. Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry. 2004;185:63–69
  4. Aramakis VB, Bandrowski AE, Ashe JH. Muscarinic reduction of GABAergic synaptic potentials results in disinhibition of the AMPA/kainate-mediated EPSP in auditory cortex. Brain Research. 1997;758:107–117
  5. Asai Y, Takano A, Ito H, Okubo Y, Matsuura M, Otsuka A, et al. GABA(A)/Benzodiazepine receptor binding in patients with schizophrenia using [(11)C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. Schizophrenia Research. 2007;99:333–340
  6. Ashton CH. Benzodiazepines: how the work and how to withdraw. 2007. http://www.benzo.org.uk/manual/index.htm2007;
  7. Baghdoyan HA. Location and quantification of muscarinic receptor subtypes in rat pons: implications for REM sleep generation. American Journal of Physiology. 1997;273:R896–R904
  8. Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS, et al. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biological Psychiatry. 1998;43:107–117
  9. Battaglia M. Beyond the usual suspects: a cholinergic route for panic attacks. Molecular Psychiatry. 2002;7:239–246
  10. Battaglia M, Bertella S, Ogliari A, Bellodi L, Smeraldi E. Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Archives of General Psychiatry. 2001;58:114–119
  11. Benes FM. Altered glutamatergic and GABAergic mechanisms in the cingulate cortex of the schizophrenic brain. Archives of General Psychiatry. 1995;52:1015–1018
  12. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. Journal of Neuroscience. 1992;12:924–929
  13. Benes FM, Vincent SL, Marie A, Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience. 1996;75:1021–1031
  14. Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Research. 1997;755:121–129
  15. Buhl EH, Tamas G, Fisahn A. Cholinergic activation and tonic excitation induce persistent gamma oscillations in mouse somatosensory cortex in vitro. Journal of Physiology. 1998;513(Pt 1):117–126
  16. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. American Journal of Psychiatry. 1997;154:56–63
  17. Colantuoni C, Hyde TM, Mitkus S, Joseph A, Sartorius L, Aguirre C, et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Structure and Function. 2008;213:255–271
  18. Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, et al. A GABAergic cortical deficit dominates schizophrenia pathophysiology. Critical Reviews in Neurobiology. 2004;16:1–23
  19. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. American Journal of Psychiatry. 2001;158:918–925
  20. Dean B. A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. Clinical and Experimental Pharmacology and Physiology. 2001;28:74–78
  21. Dean B. Is schizophrenia the price of human central nervous system complexity?. Australian and New Zealand Journal of Psychiatry. 2009;43:13–24
  22. Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, et al. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. Journal of Neurochemistry. 1999;72:1593–1599
  23. Dean B, Hussain T, Scarr E, Pavey G, Copolov DL. Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum. Life Sciences. 2001;69:1257–1268
  24. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry. 2002;7:1083–1091
  25. Dean B, Soulby A, Evin GM, Scarr E. Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophrenia Research. 2008;106:229–236
  26. Deng C, Huang XF. Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Experimental Brain Research. 2006;168:587–590
  27. Dickson CT, Alonso A. Muscarinic induction of synchronous population activity in the entorhinal cortex. Journal of Neuroscience. 1997;17:6729–6744
  28. Farnbach-Pralong D, Bradbury R, Copolov D, Dean B. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. European Journal of Pharmacology. 1998;349:R7–R8
  29. File SE, Kenny PJ, Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacology and Biochemical Behaviour. 2000;66:65–72
  30. Foster P. Neuroleptic equivalence. The Pharmaceutical Journal. 1989;243:431–432
  31. Franzblau A. A Primer of Statistics for Non-statisticians. New York: Harcourt, Brace and World; 1958;
  32. Frey JM, Ticku MK, Huffman RD. GABAergic supersensitivity within the pars reticulata of the rat substantia nigra following chronic haloperidol administration. Brain Research. 1987;425:73–84
  33. Frey JM, Ticku MK, Bell RD, Huffman RD. Chronic haloperidol administration increases GABA binding and enhances neuronal responsiveness to iontophoresed GABA in rat globus pallidus. Brain Research. 1989;491:57–67
  34. Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. Journal of Affective Disorders. 2009;116:184–191
  35. Grubb F. Procedures for detecting outlying observations in samples. Technometrics. 1969;11:1–21
  36. Han M, Newell K, Zavitsanou K, Deng C, Huang XF. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research. 2008;86:457–464
  37. Hanada S, Mita T, Nishino N, Tanaka C. [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences. 1987;40:259–266
  38. Haw C, Stubbs J. Benzodiazepines – a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. Journal of Psychopharmacology. 2007;21:645–649
  39. Hill C, Keks N, Roberts S, Opeskin K, Dean B, Mackinnon A, et al. Problem of diagnosis in postmortem brain studies of schizophrenia. American Journal of Psychiatry. 1996;153:533–537
  40. Huffman RD, Ticku MK. The effects of chronic haloperidol administration on GABA receptor binding. Pharmacology and Biochemical Behaviour. 1983;19:199–204
  41. Huntsman MM, Tran BV, Potkin SG, Bunney WE, Jones EG. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:15066–15071
  42. Iwata N, Kozuka M, Hara T, Kanek T, Tonohiro T, Sugimoto M, et al. Activation of cerebral function by CS-932, a functionally selective M1 partial agonist: neurochemical characterization and pharmacological studies. Japanese Journal of Pharmacology. 2000;84:266–280
  43. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Research Molecular Brain Research. 1995;28:311–318
  44. Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, Toru M. Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. European Archives of Psychiatry and Neurological Sciences. 1989;239:71–78
  45. Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF. Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers. Molecular Psychiatry. 2002;7:392–404
  46. Lemstra AW, Eikelenboom P, van Gool WA. The cholinergic deficiency syndrome and its therapeutic implications. Gerontology. 2003;49:55–60
  47. Lewis DA, Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical gaba neurons. International Review of Neurobiology. 2007;78:109–131
  48. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. American Journal of Psychiatry. 2008;165:1585–1593
  49. Liberatore GT, Wong JY, Krenus D, Jeffreys BJ, Porritt MJ, Howells DW. Tissue fixation prevents contamination of tritium-sensitive storage phosphor imaging plates. BioTechniques. 1999;26:432–434
  50. Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. American Journal of Medical Genetics B: Neuropsychiatry Genetics. 2003;119:2–6
  51. McLeod MC, Sundram S, Dean B. Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2008;32:560–567
  52. Mohler H. Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. Journal of Neurochemistry. 2007;102:1–12
  53. Olsen RW, Tobin AJ. Molecular biology of GABAA receptors. Federation of American Societies for Experimantal Biology Journal. 1990;4:1469–1480
  54. Pandey GN, Conley RR, Pandey SC, Goel S, Roberts RC, Tamminga CA, et al. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Research. 1997;71:137–149
  55. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Washington D.C.: Academic Press; 1986;
  56. Poitras G. More on the correct use of omnibus tests for normality. Economic Letters. 2006;90:304–305
  57. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Molecular Psychiatry. 2007;12:232–246
  58. Reynolds GP, Stroud D. Hippocampal benzodiazepine receptors in schizophrenia. Journal of Neural Transmission. General Section. 1993;93:151–155
  59. Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL. Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Australian and New Zealand Journal of Psychiatry. 1998;32:73–76
  60. Rodbard D. Mathematics and statistics of ligand assays: an illustrated guide. In:  Langan J,  Clapp JJ editor. Ligand Assay: Analysis of international developments on isotopic and nonisotopic immunoassay. New York: Masson Punlishing USA, Inc; 1981;p. 45–99
  61. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. Journal of Neurochemistry. 2008;107:1188–1195
  62. See RE, Aravagiri M, Ellison GD. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors. Life Sciences. 1989;44:229–236
  63. See RE, Toga AW, Ellison G. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. Journal of Neural Transmission. General Section. 1990;82:93–109
  64. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. American Journal of Psychiatry. 2008;165:1033–1039
  65. Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Advances in Pharmacology. 2006;54:231–263
  66. Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T. The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined. Schizophrenia Research. 2007;90:76–80
  67. Smith GB, Olsen RW. Functional domains of GABAA receptors. Trends in Pharmacological Sciences. 1995;16:162–168
  68. Squires RF, Lajtha A, Saederup E, Palkovits M. Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses?. Neurochemistry Research. 1993;18:219–223
  69. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, et al. Human postmortem tissue: what quality markers matter?. Brain Research. 2006;1123:1–11
  70. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The stanley foundation brain collection and neuropathology consortium. Schizophrenia Research. 2000;44:151–155
  71. Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, bi-Dargham A, et al. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research. 1999;91:163–173
  72. Wong G, Kuoppamaki M, Hietala J, Luddens H, Syvalahti E, Korpi ER. Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors. European Journal of Pharmacology. 1996;314:319–323
  73. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry. 2003;64:663–667
  74. Zavitsanou K, Katsifis A, Filomena M, Xu-Feng H. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology. 2004;29:619–625
  75. Zavitsanou K, Nguyen VH, Han M, Huang XF. Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors. Neurochemistry Research. 2007;32:525–532
  76. Zink M, Schmitt A, May B, Muller B, Demirakca T, Braus DF, et al. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophrenia Research. 2004;66:151–157

PII: S0165-1781(09)00135-8

doi: 10.1016/j.psychres.2009.03.034

Psychiatry Research
Volume 179, Issue 2 , Pages 139-146 , 30 September 2010

Article Tools

* Image Usage & Resolution